6--pterin | 34793-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 6--pterin
• 英文别名: 2-amino-6-[(4-methylanilino)methyl]-3H-pteridin-4-one
• CAS: 34793-25-4
• 化学式: C₁₄H₁₄N₆O
• 分子量: 282.305
• InChiKey: QYKACTDQMUOZAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER<br/>[FR] SYNTHÈSE ET COMPOSITION D'AGENTS THÉRAPEUTIQUES PHOTODYNAMIQUES POUR LE TRAITEMENT CIBLÉ DU CANCER
  申请人：ON TARGET LABORATORIES LLC

  公开号：WO2017044443A1

  公开（公告）日：2017-03-16

  The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.

  本发明描述了一种新的化合物，可用于图像引导手术和光动力疗法。特别是，化合物可以通过使用针对表达在患病组织上的受体的配体将化合物输送到疾病组织（如癌症），然后通过受体介导的内吞作用定位到细胞核或线粒体，并对癌细胞以及其他疾病提供有效的活性。同时还描述了使用该化合物的方法和组合物。
• Metal Complexes Derivatized with Folate for use in Diagnostic and Therapeutic Applications
  申请人：Wedeking W. Paul

  公开号：US20070077197A1

  公开（公告）日：2007-04-05

  Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the α, γ, or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.

  诊断和治疗复合物的形式，用于增强诊断或治疗剂的跨膜转运，以及它们的使用方法。这些复合物包含叶酸受体结合叶酸的α，γ或双异构体类似物，由配体螯合的金属，以及在某些情况下，化疗药物。
• IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS
  申请人：Low Philip Stewart

  公开号：US20100226967A1

  公开（公告）日：2010-09-09

  The invention relates to a method of treating or diagnosing a disease state worsened by progenitor cells. The method utilizes a composition comprising a conjugate or complex of the general formula A b -X wherein the group A b comprises a vitamin, or an analog thereof, that binds to progenitor cells, and when the conjugate is being used for treatment of the disease state, the group X comprises an antigen, a cytotoxin, or a compound capable of altering progenitor cell function, and when the conjugate is being used for diagnosing the disease state, the group X comprises a quantifiable marker.

  本发明涉及一种治疗或诊断由祖细胞恶化引起的疾病状态的方法。该方法利用包含通式Ab-X的共轭物或复合物的组合物，其中Ab组包括维生素或其类似物，该维生素或其类似物与祖细胞结合。当该共轭物用于治疗疾病状态时，组X包括抗原、细胞毒素或能够改变祖细胞功能的化合物；当该共轭物用于诊断疾病状态时，组X包括可量化的标记物。
• FOLATE-TARGETED DIAGNOSTICS AND TREATMENT
  申请人：Leamon Christopher Paul

  公开号：US20120128587A1

  公开（公告）日：2012-05-24

  Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described are methods and compositions for treating folate receptor expressing epithelial tumors with a folate-vinca conjugate in combination with doxorubicin such as pegylated liposomal doxorubicin in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum sensitive ovarian tumors. Also described are methods of treating platinum-resistant ovarian cancer using a folate-targeted drug, in the absence or presence of selecting the patient by identifying functionally active folate receptors on the tumors of the patient.

  本文描述了检测和评估肿瘤上功能活性叶酸受体的方法以及与该类肿瘤相关的治疗方法。还描述了通过识别患者肿瘤上功能活性叶酸受体，选择卵巢和肺癌患者使用叶酸-长春瑞滨偶联物疗法的方法。此外，还描述了使用叶酸-长春瑞滨偶联物和多柔比星（如聚乙二醇化脂质体多柔比星）联合治疗表达叶酸受体的上皮性肿瘤的方法和组合物，其中包括卵巢、子宫内膜和非小细胞肺癌肿瘤，包括铂类耐药性卵巢肿瘤和铂类敏感性卵巢肿瘤。此外，还描述了使用叶酸靶向药物治疗铂类耐药性卵巢癌的方法，无论是否通过识别患者肿瘤上功能活性叶酸受体进行患者选择。
• CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS
  申请人：Leamon Christopher Paul

  公开号：US20100323973A1

  公开（公告）日：2010-12-23

  Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.

  本文描述了一种使用细胞受体结合药物递送共轭物质的组合物和方法，其中包含亲水性空间连接剂，用于成像、诊断和/或治疗由致病细胞群体引起的疾病和疾病状态的靶向药物递送。